Key Highlights
- Carterra’s 2025 global symposia spotlight AI/ML breakthroughs in high-throughput drug discovery and antibody engineering
- Strategic collaboration with Pfizer, GSK, and academic innovators aims to fast-track biologics using AI-powered SPR platforms
- Carterra to unveil new Ultra™ platform data, setting new standards in AI-integrated, high-throughput molecular analytics
AI at the Core of the Next Drug Discovery Wave
Carterra Inc., a front-runner in high-throughput biology, has launched its 2025 global symposia series, bringing together leading AI-driven drug discovery experts from Pfizer, GSK, Bio-Techne, and top universities. With sessions focused on AI and machine learning in protein engineering, multifunctional antibodies, and epitope mapping, the events are designed to accelerate the integration of intelligent automation into therapeutic pipelines.
Power Players Collaborate to Rewire R&D Through AI
Held across biotech hubs in Boston, Munich, Cambridge, and San Francisco, the symposia will feature top researchers from Pfizer, GSK, University of Pennsylvania, University of Oxford, Ordaos, and more. Their talks will explore the convergence of AI with biophysical data to optimize the speed, precision, and scalability of biologic discovery—making the events a pivotal moment for translational research.
Unveiling Carterra Ultra™: AI-Enhanced Drug Discovery at Speed and Scale
Carterra will present the first performance data from its Ultra™ platform, announced in late 2024. Designed to address both small and large molecule R&D, the Ultra platform combines high-throughput microfluidics and SPR with minimal sample input. When paired with AI models, it enables researchers to generate richer datasets for accelerated molecule ranking, target validation, and therapeutic optimization.
A Strategic Forum for Biopharma’s AI Future
These symposia aren’t just scientific—they are strategic. Designed for C-level scientists and innovation leads, they offer unique opportunities for collaboration, data-sharing, and AI integration. Co-hosts IPA, ACROBiosystems, and Curia add strength to the ecosystem, ensuring discussions remain application-focused and commercially impactful. Register here to join the AI-driven transformation of drug discovery.
About Carterra
Carterra® develops cutting-edge high-throughput platforms—LSA, LSAXT, and Ultra™—that redefine the pace of biotherapeutic and small molecule discovery. Integrating patented microfluidics with AI-ready, high-resolution Surface Plasmon Resonance (HT-SPR), Carterra enables pharma to screen more candidates, faster and more accurately, with up to 100x the throughput using 1% of the sample volume. Its platforms are setting new industry standards in precision, speed, and scalability.
By
